How Are These Pathways Targeted in Cancer Therapy?
Targeting dysregulated signal transduction pathways has become a cornerstone of modern cancer therapy. Small molecule inhibitors and monoclonal antibodies are designed to specifically inhibit key components of these pathways. For example, tyrosine kinase inhibitors (TKIs) target abnormal kinase activity in the PI3K/AKT/mTOR and MAPK/ERK pathways. Immunotherapies can also modulate these pathways to enhance anti-tumor immune responses.
